FDA ap­proves Al­ler­gan's newest hyaluron­ic acid in­jectable — with a new de­liv­ery sys­tem

FDA gave the green light to Al­ler­gan Aes­thet­ics’ new de­liv­ery method for hyaluron­ic acid on Mon­day — open­ing up a new route of ad­min­is­ter­ing pre­scrip­tion beau­ty prod­ucts.

The Ab­b­Vie sub­sidiary is brand­ing the in­tra­der­mal mi­cro­droplet in­jec­tion as Skin­vive by Ju­vé­derm. The in­jectable con­tains a small amount of li­do­caine, a top­i­cal anes­thet­ic.

Ju­vé­derm al­ready has sev­er­al oth­er in­jectable hyaluron­ic acid for­mu­la­tions in its port­fo­lio, work­ing as der­mal fillers for dif­fer­ent parts of the face such as chin, lips, or the jaw­line, ac­cord­ing to its web­site. The new prod­uct is in­di­cat­ed for skin smooth­ness in the cheeks for adults ages 21 and old­er.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER